Your browser doesn't support javascript.
loading
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
Morita, Atsuhiro; Tamaki, Nobuharu; Kobashi, Haruhiko; Mori, Nami; Tsuji, Keiji; Takaki, Shintaro; Hasebe, Chitomi; Akahane, Takehiro; Ochi, Hironori; Mashiba, Toshie; Urawa, Naohito; Fujii, Hideki; Mitsuda, Akeri; Kondo, Masahiko; Ogawa, Chikara; Uchida, Yasushi; Narita, Ryoichi; Marusawa, Hiroyuki; Kubotsu, Yoshihito; Matsushita, Tomomichi; Shigeno, Masaya; Yoshida, Hideo; Tanaka, Katsuaki; Okamoto, Eisuke; Kasai, Toyotaka; Ishii, Toru; Okada, Kazuhiko; Kurosaki, Masayuki; Izumi, Namiki.
Afiliación
  • Morita A; Department of Gastroenterology Japanese Red Cross Kyoto Daini Hospital Kyoto Japan.
  • Tamaki N; Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
  • Kobashi H; Department of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan.
  • Mori N; Department of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
  • Tsuji K; Department of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
  • Takaki S; Department of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
  • Hasebe C; Department of Gastroenterology Japanese Red Cross Asahikawa Hospital Asahikawa Japan.
  • Akahane T; Department of Gastroenterology Ishinomaki Red Cross Hospital Ishinomaki Japan.
  • Ochi H; Center for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan.
  • Mashiba T; Center for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan.
  • Urawa N; Department of Gastroenterology and Hepatology Ise Red Cross Hospital Ise Japan.
  • Fujii H; Department of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Mitsuda A; Department of Gastroenterology Tottori Red Cross Hospital Tottori Japan.
  • Kondo M; Department of Gastroenterology Otsu Red Cross Hospital Otsu Japan.
  • Ogawa C; Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan.
  • Uchida Y; Department of Gastroenterology Matsue Red Cross Hospital Matsue Japan.
  • Narita R; Department of Gastroenterology Oita Red Cross Hospital Oita Japan.
  • Marusawa H; Department of Gastroenterology and Hepatology Osaka Red Cross Hospital Osaka Japan.
  • Kubotsu Y; Department of Internal Medicine Karatsu Red Cross Hospital Saga Japan.
  • Matsushita T; Department of Gastroenterology Japanese Red Cross Gifu Hospital Gifu Japan.
  • Shigeno M; Department of Gastroenterology Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan.
  • Yoshida H; Department of Gastroenterology Japanese Red Cross Medical Center Tokyo Japan.
  • Tanaka K; Department of Gastroenterology Hatano Red Cross Hospital Hatano Japan.
  • Okamoto E; Department of Gastroenterology Masuda Red Cross Hospital Masuda Japan.
  • Kasai T; Department of Gastroenterology Fukaya Red Cross Hospital Saitama Japan.
  • Ishii T; Department of Gastroenterology Japanese Red Cross Akita Hospital Akita Japan.
  • Okada K; Department of Gastroenterology Toyama Red Cross Hospital Toyama Japan.
  • Kurosaki M; Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
  • Izumi N; Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
JGH Open ; 8(4): e13068, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38681824
ABSTRACT
Background and

aim:

In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non-cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated.

Methods:

This prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non-cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated.

Results:

The SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups (P = 0.4).

Conclusion:

GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JGH Open Año: 2024 Tipo del documento: Article Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JGH Open Año: 2024 Tipo del documento: Article Pais de publicación: Australia